ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Allergan (AGN)
DateTimeHeadline
07/30/201510:00:11Teva Profit Falls on Legal Expenses
07/30/201508:00:00Allergan Confirms Generic Tyvaso® Patent Challenge
07/29/201508:30:05Mylan Gets European Regulator's Approval for Perrigo Deal
07/29/201508:05:58Mylan Gets European Regulator's Approval for Perrigo Deal
07/28/201508:53:36Current Report Filing (8-k)
07/27/201519:48:05Mylan's Leverage to Resist Teva Deal Reveals Shift in Rules
07/27/201517:22:53Current Report Filing (8-k)
07/27/201517:10:14Mylan's Leverage to Resist Teva Deal Reveals Shift in Rules
07/27/201517:07:41Current Report Filing (8-k)
07/27/201516:45:00Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino...
07/27/201510:11:55Teva to Buy Allergan Generics for $40.5 Billion -- 7th Update
07/27/201509:01:32Teva to Buy Allergan Generics for $40.5 Billion -- 6th Update
07/27/201509:00:04U.S. Stock Futures Follow Global Markets Lower
07/27/201508:35:11Teva to Buy Allergan Generics for $40.5 Billion -- 5th Update
07/27/201508:13:47Teva to Buy Allergan Generics for $40.5 Billion -- 4th Update
07/27/201507:51:32Teva to Buy Allergan Generics for $40.5 Billion -- 3rd Update
07/27/201506:30:03Teva to Buy Allergan Generics for $40.5 Billion
07/27/201506:28:03Teva to Buy Allergan Generics for $40.5 Billion -- 2nd Update
07/27/201506:03:20Teva to Buy Allergan Generics for $40.5 Billion -- Update
07/27/201505:37:30Teva to Buy Allergan Generics for $40.5 Billion

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad